Working… Menu

Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00407121
Recruitment Status : Completed
First Posted : December 4, 2006
Last Update Posted : December 4, 2006
Information provided by:
Asociación para Evitar la Ceguera en México

Brief Summary:
Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Condition or disease Intervention/treatment Phase
Vogt Koyanagi Harada Disease Serpiginous Choroiditis Multifocal Choroiditis Drug: Bevacizumab Procedure: Intravitreal Injection of Bevacizumab Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation
Study Start Date : August 2006
Study Completion Date : November 2006

Primary Outcome Measures :
  1. Best corrected visual acuity
  2. Retinal thickness by OCT
  3. Leakage in Fluorescein angiogram

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical Diagnose
  • Patient Consent
  • Chronic stage of inflammation

Exclusion Criteria:

  • only eye
  • age lower than 30 yo.
  • Systemic condition

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00407121

Layout table for location information
Asociacion para Evitar la Ceguera en Mexico
Mexico, Distrito Federal, Mexico, 04030
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Layout table for investigator information
Principal Investigator: Veronica Kon-Jara, MD Asociación para Evitar la Ceguera en México
Study Chair: LuzElena Concha-Del Rio, MD Asociación para Evitar la Ceguera en México
Layout table for additonal information Identifier: NCT00407121    
Other Study ID Numbers: APEC-0025
First Posted: December 4, 2006    Key Record Dates
Last Update Posted: December 4, 2006
Last Verified: December 2006
Keywords provided by Asociación para Evitar la Ceguera en México:
Neovascular Membrane
Additional relevant MeSH terms:
Layout table for MeSH terms
Uveomeningoencephalitic Syndrome
Choroid Diseases
Uveal Diseases
Eye Diseases
Uveitis, Posterior
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Autoimmune Diseases
Immune System Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors